We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioject Establishes Strategic Alliance with MPI Research
News

Bioject Establishes Strategic Alliance with MPI Research

Bioject Establishes Strategic Alliance with MPI Research
News

Bioject Establishes Strategic Alliance with MPI Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioject Establishes Strategic Alliance with MPI Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioject Medical Technologies Inc. has announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.

“Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry. It is a pleasure to collaborate with a company that has such highly-developed technological expertise and strategic vision.”

The strategic alliance creates a preferred partnership relationship which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore our drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research.

The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers who may be interested in seeking a highly competitive and differentiable drug+device brand.

This alliance also increases the possibility that Bioject and MPI Research may be able to secure government sponsored grants or funding directed at improvements in drug+device or vaccine+device based treatments, which could also lead to potential new drug+device combinations.
Advertisement